HOUSTON (UPI) -- A drug that targets cell surface receptors may shrink breast cancer tumors in six weeks, a U.S. scientist reports.
Dr. Angel Rodriguez of Baylor College of Medicine in Houston says the drug -- a tyrosine kinase inhibitor known as lapatinib -- could decrease tumor-causing breast cancer stem cells in women receiving treatment given before primary surgery. Rodriguez and colleagues studied 45 patients with locally advanced breast cancer in which the gene HER-2 was over-expressed.
The patients received lapatinib for six weeks, followed by a combination of weekly trastuzumab and thrice-weekly docetaxel, given over 12 weeks, before primary surgery. Biopsies were performed at the time of diagnosis and also after six weeks of lapatinib and cells from the tumors were obtained and analyzed.
"We saw significant tumor regression after six weeks of single-agent lapatinib," Rodriguez said in a statement. "Bi-dimensional tumor measurements showed a median decrease of minus 60.8 percent." The findings are being presented at the sixth European Breast Cancer Conference in Berlin.
Copyright 2008 by United Press International
arcamax.com
Subscribe to:
Post Comments (Atom)
Black Women are also Beautiful!
“Sponsored post. All opinions are mine.” I can't imagine that weekend is almost ending! And yes, it is the last weekend of the Janu...
-
You might know some Filipinos cultures? Filipinos always have close family ties and wherever they are around the world, they always remember...
-
I just want to share one of the most important Law in Germany. I believed this is good to share especially to those persons who live in Ge...
-
Vaduz is not really a big city since Liechtenstein is also a small country. Vaduz is the capital of the principality of Liechtenstein and ...
No comments:
Post a Comment